Overview

Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir
Rosuvastatin Calcium